Skip to main content
Premium Trial:

Request an Annual Quote

Cell Signaling Technology to Conduct Pilot Study for AstraZeneca to Find Biomarkers of Target Inhibition

NEW YORK, June 8 (GenomeWeb News) - Cell Signaling Technology will perform a pilot study for AstraZeneca to find biomarkers of target inhibition using its phospho-proteomics technology, the company said yesterday.


Cell Signaling, based in Beverly, Mass., will study compounds provided by AstraZeneca to find cellular protein tyrosine kinase phosphorylation profiles that indicate target inhibition.


The company will employ its Global Phospho-Signature technology, which combines immunoaffinity purification and mass spectrometry.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.